Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase EARLY_PHASE1 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Breast 2

Conditions

Breast Neoplasms 22Endometrial Neoplasms 3Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sexual Dysfunctions, Psychological 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1HR+/HER2- Breast Cancer 1HER2-positive Breast Cancer 1Fallopian Tube Neoplasms 1Endometrioid Endometrial Cancer 1Carcinoma, Ovarian Epithelial 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms, Male 1Breast Diseases 1Breast Carcinoma In Situ 1Anatomic Stage I Breast Cancer AJCC v8 1Advanced Unresectable or Metastatic Breast Cancer of Adults 1Advanced Solid Tumor 1

Interventions

Docetaxel 33Prednisone 28enzalutamide 19Abiraterone Acetate 13pembrolizumab 11gallium 68 PSMA-11 9Leuprolide 9Radiotherapy 8Pluvicto 8Magnetic Resonance Spectroscopy 8Nivolumab 7Estramustine 7abiraterone 6Radiotherapy, Intensity-Modulated 6Goserelin 6Carboplatin 6Biopsy 6olaparib 5cemiplimab 5bicalutamide 5Specimen Handling 5Paclitaxel 5Cyclophosphamide 5temsirolimus 4orteronel 4darolutamide 4cabazitaxel 4acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 4Sirolimus 4Radiosurgery 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Prostatic Neoplasms × Letrozole × Clear all
NCT07288359 2026-05-27

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Novartis

Phase 1/2 Recruiting
205 enrolled
BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT07570966 2026-05-06

Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Novartis

Phase 1/2 Not yet recruiting
217 enrolled
BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡